Právní předpis byl sestaven k datu 17.02.2025.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx dopingu xxx rok 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu o xxxxxxx změn Přílohy X Českou republikou.
Nové xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x platnost xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.
Xxxxxxxx znění Xxxxxxx X xxx xxx 2024 x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Xx.X., XX.X., x. r.
vrchní ředitel xxxxx právní x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Překlad xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx a metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx je každoročně xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam je xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx WADA a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx mezi anglickým x xxxxxxxxxxxx textem xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx xxxx uvedeny xxxxxxx pojmy xxxxxxxxx x xxxxx Seznamu xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx soutěži
Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, je období Xxx soutěži x xxxxxx xxxxxxx začínajícím xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx zúčastnit, xx do xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx xxxxx
Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx zakázána Při xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Nespecifické
Podle článku 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Xxxxxxx xxxxxxxxx označena jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx nebezpečné xxx xxxx dopingové xxxxx xxxx xxxxxx. Xxx xxxxx o xxxxx x metody, xxxxx Sportovec pravděpodobně xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx xxxxxxxx z xxxxxx jejich xxxxxxx xxxxxxxxxx ve společnosti xxxx xxxxx sportu. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).
S0 XXXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj xxx xxxxxxx, syntetické drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.
Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (PŘI XXXXXXX I MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx jiné xxxxxx:
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
• |
1-androstenedion (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
• |
4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
• |
xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol) |
• |
norboleton |
|
• |
androstenedion (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
• |
calusteron |
• |
oxymesteron |
|
• |
klostebol |
• |
oxymetolon |
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
• |
xxxxxxxxxxxx (19-norpregna-4-en-17α-ol) |
• |
trenbolon (17β-hydroxyestr-4,9,11-trien-3-on) |
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými účinky.
S1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (ligandrol), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.
X2 PEPTIDOVÉ HORMONY, XXXXXXX FAKTORY, XXXXXXXX XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX XXXXXXX X MIMO SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx jiné včetně:
S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.
S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.
S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx EPO (CEPO).
S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX
X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x mužů, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (CG),
• xxxxxxxxxxxx xxxxxx (LH),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx a xxxxxx uvolňující faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx analogy x xxxxxxxxx, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x hGH 176–191.
X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x jejich xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],
• xxxxxxx uvolňující GH (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].
X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxxxxxxx růstový xxxxxx (HGF)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO SOUTĚŽ)
Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv xxxxx;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx za 24 hodin.
POZNÁMKA
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxx vyšším než 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx dávky (inhalační) xx xx výše xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx S4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (xxxxxxxxx) |
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
• |
xxxxxxxxxx |
X4.2. ANTIESTROGENNÍ LÁTKY [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx xxxx xxxxxx:
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX RECEPTORU AKTIVINU XXX
Xxxx xxxx včetně:
• |
protilátky xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx expresi myostatinu |
||
- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx) |
|||
• |
xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, GW501516) x xxxxxxxx Xxx-xxxɑ , např. SR9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx zakázány.
Mimo xxxx xxxxxx:
•&xxxx; Xxxxxxxxx, xxxx např.:
acetazolamid; amilorid; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Vaptany, xxxx. konivaptan, mozavaptan, xxxxxxxxx;
• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;
• Desmopresin;
• Xxxxxxxxxx;
x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x zubní xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu v xxxxxxxx xxxxxxxxx), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou výjimku (XX) xx xxxx xxxxx xxxxx k xx, která již xxxx udělena xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.
XXXXXXXX METODY
ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx plazmy xxxx xxxxxx složek Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx a modifikované xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx náhražky xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx kontrole.
Mimo jiné xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X XXXXXXX DOPING
Z xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx genů x xxxxxxxxxxx přenosů xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX PŘI XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Specifické xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx v xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, např. x- x x-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
• |
xxxxxxxxxxx |
|||
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.
X6.X: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx včetně:
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
• |
3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
• |
xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia xxxxxxxx xx Monitorovacího programu 20245).
X7 NARKOTIKA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x této xxxxx: diamorfin (heroin)
Následující xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x l, xxxx xxxxxxxx.
• |
xxxxxxxxxxx |
• |
xxxxxxxx a jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny zakázané xxxxx x této xxxxx xxxx Specifické xxxxx. Xxxxxxxx látky x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• přírodní a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.
Všechny xxxxxxxxxxxxxxx xxxx zakázány, xxxxx xxxx xxxxxxxx jakoukoliv xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx xxxxxx.
Xxxx xxxx xxxxxx:
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx se xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx to označeno xxxxxxxx (*) x Xxxx xxxxxx.
• lukostřelba (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx a xxxxxxxxx U-rampa / xxx air
• automobilový xxxxx (FIA)
• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx
• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
• xxxxx (WDF)
• xxxx (XXX)
• xxxxxxxx (XXX)
• střelba (ISSF, XXX)*
* xxxxxxxx xxxx Xxxx soutěž
Mimo xxxx xxxxxx:
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx č. 2
Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx jazyce
1) xxxxx (x-xxxxxxxxxxxxxxxx) x jeho x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x moči vyšší xxx 5 xxxxxxxxxx x 1 ml.
2) xxxxxxxxxxxxx: zakázaný pouze xxx xxxxxxxxxxx v xxxx vyšší xxx 150 xxxxxxxxxx x 1 ml.
3) efedrin x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx v xxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx.
4) epinefrin (xxxxxxxxx): není zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, nebo xxxxxxxx podávání x xxxxxxxxx xxxxxxxxxx.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Zakázané xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 19/2025 Xx. nabyl xxxxxxxxx dnem 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, pokud se xxxx xxxxxx derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx